CMP: $143

Biogen Idec Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company's products addresses diseases such as multiple sclerosis, non-Hodgkin's lymphoma, rheumatoid arthritis, crohn's disease, and psoriasis.

Biogen Idec is a $34 Billion market cap company trading at a P/E of 25. Revenues have risen from $4.38 Billion to $5.05 Billion in the last 2 years. Profits have risen from $970 Million to $1.23 Billion in the last 2 years. Profit margins have risen from 22% to nearly 25% in the last 2 years. Its looks a good buy for long term.